Clinical trials: Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Lung Cancer
Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00096226
- Testing
- Induction Carboplatin, Induction Paclitaxel, Resection
- Where
- 22 sites in United States
- Volunteers
- 60 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114192
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Virginia
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
This phase II trial is studying how well bortezomib works in treating patients with stage IIIB or stage IV lung cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT00118144
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Stage IIIB Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Circulating Tumor Cells in Lung Cancer
TITLE : Circulating tumor cells identification in advanced stage non-small cell lung cancer (CIRCUBRONCH) BACKGROUND : Circulating tumor cells identification is a new field of research in oncology, and some studies have been…
- Trial name
- CIRCUBRONCH (NCT01658332)
- Testing
- blood samples
- Where
- France
- Volunteers
- 59 people
- Sponsor
- Central Hospital, Nancy, France
Lung Cancer
Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293280
- Testing
- lomustine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Febrile Neutropenia, Stage 0 Breast Cancer
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia.
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer
- Trial name
- TrACER (NCT02728596)
- Testing
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 160 sites in United States, Puerto Rico
- Volunteers
- 3,665 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00970684
- Testing
- bevacizumab, docetaxel, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Nathan Pennell, MD, PhD
Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
This trial studies the side effects and how well nintedanib works compared to a placebo in treating against radiation-induced pneumonitis (inflammation of the lungs) in patients with non-small cell lung cancer that cannot be…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
- Trial name
- NCT02452463
- Testing
- Durvalumab, Nintedanib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Marimastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of marimastat in treating patients who…
- Trial name
- NCT00002911
- Testing
- marimastat
- Where
- 50 sites in United States, Canada
- Sponsor
- ILEX Oncology Services, Incorporated
Breast Cancer, Colorectal Cancer
Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors
RATIONALE: Chemotherapy may cause blood clots to form in the thigh, leg, and lung. This study may help doctors understand how often blood clots occur in patients undergoing chemotherapy.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00433602
- Testing
- clinical observation, management of therapy complications, ultrasound imaging
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer
Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00039039
- Testing
- carboplatin, chemotherapy, cisplatin
- Where
- 37 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer, Colorectal Cancer
CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00033384
- Testing
- CI-1040
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer
This randomized phase I trial is studying the side effects and best dose of suramin when given together with either docetaxel or gemcitabine in treating patients with stage IIIB or stage IV non-small cell lung cancer that is…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00066768
- Testing
- suramin, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02503722
- Testing
- Laboratory Biomarker Analysis, Osimertinib, Pharmacological Study
- Where
- 5 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of hypofractionated radiation therapy when given together with chemotherapy in treating patients with stage III non-small cell lung cancer that cannot be removed by…
- Trial name
- NCT01486602
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than…
- Conditions
- Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT04892953
- Testing
- Carboplatin, Durvalumab, Gemcitabine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients with non-small cell lung cancer that cannot be surgically…
- Trial name
- NCT00002577
- Testing
- radiation therapy
- Where
- 242 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Radiation Therapy Oncology Group
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
This randomized phase III trial studies pemetrexed disodium to see how well it works compared with erlotinib hydrochloride as second-line therapy in treating patients with non-small cell lung cancer that has spread to other…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- MARVEL (NCT00738881)
- Testing
- Erlotinib Hydrochloride, Pemetrexed Disodium
- Where
- 269 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00020709
- Testing
- cisplatin, docetaxel, etoposide
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether erlotinib is more effective than a placebo in treating non-small cell lung cancer.
- Trial name
- TOPICAL (NCT00275132)
- Testing
- erlotinib hydrochloride
- Where
- United Kingdom
- Volunteers
- 670 people
- Sponsor
- University College, London